A Phase 2 randomized, double-blind, placebocontrolled, multi-center study to evaluate the safety and efficacy of the oral, gut-restricted ɑ4β7 integrin peptide antagonist PN-943

A Phase 2 randomized, double-blind, placebocontrolled, multi-center study to evaluate the safety and efficacy of the oral, gut-restricted ɑ4β7 integrin peptide antagonist PN-943 in patients with moderate to severe ulcerative colitis: the IDEAL Study

DOWNLOAD PUBLICATION